Ivacaftor
Brand names: Symdeko · Active ingredient: Ivacaftor
In short: SYMDEKO is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on i
What is Ivacaftor used for?
SYMDEKO is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence .
If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.
Ivacaftor dosage
Swallow the tablets whole.
SYMDEKO should be taken with fat-containing food, such as food recommended in standard nutritional guidelines. Examples of meals or snacks that contain fat are those prepared with butter or oils or those containing eggs, cheeses, nuts, whole milk, or meats, etc. .
Adults, adolescents, and children aged 6 years and older should be dosed according to Table 1. The morning and the evening doses should be taken approximately 12 hours apart.
Age | Morning(one tablet) | Evening(one tablet)
6 to <12 years weighing <30 kg | tezacaftor 50 mg/ivacaftor 75 mg | ivacaftor 75 mg
6 to <12 years weighing ≥30 kg | tezacaftor 100 mg/ivacaftor 150 mg | ivacaftor 150 mg
≥12 years | tezacaftor 100 mg/ivacaftor 150 mg | ivacaftor 150 mg
Information for Missed Doses:
If 6 hours or less have passed since the missed morning or evening dose, the patient should take the missed dose as soon as possible and continue on the original schedule. If more than 6 hours have passed since the missed morning or evening dose, the patient should not take the missed dose. The next scheduled dose can be taken at the usual time. More than one dose should not be taken at the same time.
For dosage adjustment for patients with hepatic impairment, refer to Table 2.
Studies have not been conducted in patients with severe hepatic impairment (Child-Pugh Class C), but exposure of tezacaftor and ivacaftor is expected to be higher than in patients with moderate hepatic impairment. Therefore, SYMDEKO should be used with caution at an adjusted dosage after weighing the risks and benefits of treatment in these patients [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Patient Counseling Information (17)].
Hepatic Impairment | Morning | Evening
Patients Aged 6 to <12 Years Weighing <30 kg | Patients Aged 6 to <12 Years Weighing ≥30 kg and Patients Age ≥12 Years | All Patients
Mild (Child-Pugh Class A) | No dose adjustment | No dose adjustment | No dose adjustment
Moderate (Child-Pugh Class B) | One tablet of tezacaftor 50 mg/ivacaftor 75 mg once daily | One tablet of tezacaftor 100 mg/ivacaftor 150 mg once daily | No ivacaftor dose
Severe (Child-Pugh Class C) | One tablet of tezacaftor 50 mg/ivacaftor 75 mg once daily(or less frequently) | One tablet of tezacaftor 100 mg/ivacaftor 150 mg once daily(or less frequently)
The dosing regimen of SYMDEKO should be adjusted when co-administered with moderate and strong CYP3A inhibitors.
Moderate CYP3A inhibitors:
When co-administered with moderate CYP3A inhibitors (e.g., fluconazole, erythromycin), the dosing regimen should be adjusted as in Table 3 [see Drug Interactions (7.2), Clinical Pharmacology (12.3), and Patient Counseling Information (17)]. …
How to take Ivacaftor — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Transaminase (ALT or AST) Elevations and Monitoring
Inform patients that elevation in liver tests has occurred in patients treated with SYMDEKO or with ivacaftor alone. Transaminases (ALT and AST) should be assessed prior to initiating SYMDEKO, every 3 months during the first year of treatment, and annually thereafter. More frequent monitoring should be considered in patients with a history of transaminase elevations .
Hypersensitivity Reactions, Including Anaphylaxis
Hypersensitivity reactions including anaphylaxis are possible with use of SYMDEKO. Inform patients of the early signs of hypersensitivity reactions including rash, hives, itching, facial swelling, tightness of the chest and wheezing. Advise patients to discontinue use of SYMDEKO immediately and contact their physician or go to the emergency department if these symptoms occur.
Intracranial Hypertension
Inform patients that intracranial hypertension has occurred in patients who received drugs containing the same or similar active ingredients as SYMDEKO. …
Warnings & precautions
Do not take this medicine if: None.
Elevated transaminases have been observed in patients with CF treated with SYMDEKO, as well as with ivacaftor monotherapy. Assessments of transaminases (ALT and AST) are recommended for all patients prior to initiating SYMDEKO, every 3 months during the first year of treatment, and annually thereafter. For patients with a history of transaminase elevations more frequent monitoring should be considered. In the event of significant elevations of transaminases, e.g., patients with ALT or AST >5 × upper limit of normal (ULN), or ALT or AST >3 × ULN with bilirubin >2 × ULN, dosing should be interrupted and laboratory tests closely followed until the abnormalities resolve. Following the resolution of transaminase elevations consider the benefits and risks of resuming treatment .
Hypersensitivity reactions, including cases of anaphylaxis, have been reported in the postmarketing setting . If signs or symptoms of serious hypersensitivity reactions develop during treatment, discontinue SYMDEKO and institute appropriate therapy. Consider the benefits and risks for the individual patient to determine whether to resume treatment with SYMDEKO.
Cases of intracranial hypertension (IH) have been reported in the postmarketing setting with the use of drugs containing the same or similar active ingredients as SYMDEKO . Clinical manifestations of IH include headache, blurred vision, diplopia, and potential vision loss; papilledema can be found on fundoscopy. If an unusual headache or visual disturbances occur during treatment, and IH is suspected, interrupt SYMDEKO and refer for prompt medical evaluation. Consider the benefits and risks for the individual patient to determine whether to resume treatment with SYMDEKO. Patients should be monitored until IH resolution and for recurrence. Patients with elevated vitamin A levels may be at increased risk. …
Ivacaftor side effects
The following adverse reactions are discussed in greater detail in other sections of the label:
Transaminase Elevations
Hypersensitivity Reactions, Including Anaphylaxis
Intracranial Hypertension
Neuropsychiatric Events, Including Suicidal Thoughts and Behaviors
Cataracts
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The overall safety profile of SYMDEKO is based on data from 1001 patients in three double-blind, placebo-controlled, clinical trials: two parallel-group trials of 12 and 24-week duration and one cross-over design trial of 8 weeks duration. Eligible patients were also able to participate in an open-label extension safety study (up to 96 weeks of SYMDEKO). In the three placebo-controlled trials (Trials 1, 2, and 3), a total of 496 patients with CF aged 12 years and older received at least one dose of SYMDEKO. The proportion of patients who discontinued study drug prematurely due to adverse reactions was 1.6% for SYMDEKO-treated patients and 2.0% for placebo-treated patients. Serious adverse reactions, whether considered drug-related or not by the investigators, that occurred more frequently in SYMDEKO-treated patients compared to placebo included distal intestinal obstruction syndrome, 3 (0.6%) SYMDEKO-treated patients vs. 0 placebo. …
Drug interactions
Potential for other drugs to affect tezacaftor/ivacaftor
Tezacaftor and ivacaftor are substrates of CYP3A (ivacaftor is a sensitive substrate of CYP3A). Concomitant use of CYP3A inducers may result in reduced exposures and thus reduced SYMDEKO efficacy. Co-administration of ivacaftor with rifampin, a strong CYP3A inducer, significantly decreased ivacaftor exposure (area under the curve [AUC]) by 89%. Tezacaftor exposures can also be expected to decrease significantly during co-administration with strong CYP3A inducers. Therefore, co-administration of SYMDEKO with strong CYP3A inducers is not recommended [see Warnings and Precautions (5.5), Clinical Pharmacology (12.3), and Patient Counseling Information (17)].
Examples of strong CYP3A inducers include:
rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, and St. John's wort (Hypericum perforatum)
Co-administration with itraconazole, a strong CYP3A inhibitor, increased tezacaftor exposure (AUC) by 4.0-fold and ivacaftor by 15.6-fold. When co-administered with strong CYP3A inhibitors, the dosing regimen of SYMDEKO should be adjusted [see Dosage and Administration (2.4), Clinical Pharmacology (12.3), and Patient Counseling Information (17)]. …
About this medicine
SYMDEKO is co-packaged as a tezacaftor/ivacaftor fixed-dose combination tablet and an ivacaftor tablet. Both tablets are for oral administration.
Tezacaftor 50 mg/ivacaftor 75 mg fixed-dose combination tablets and ivacaftor 75 mg tablets:
The tezacaftor/ivacaftor fixed-dose combination tablet is available as a white, oblong-shaped, film-coated tablet containing 50 mg of tezacaftor, 75 mg of ivacaftor, and the following inactive ingredients: croscarmellose sodium, hypromellose, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose and sodium lauryl sulfate. The tablet film coat contains HPMC/hypromellose 2910, hydroxypropyl cellulose, talc and titanium dioxide.
The ivacaftor tablet is available as a light blue, oblong-shaped, film-coated tablet containing 75 mg of ivacaftor and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 302ae804-37db-44fd-ac2f-3dbdeda9aa4b. Read the full official label on DailyMed.